Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS KRAS Cancer Connects

Phase 1 trial Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumors

Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations.

Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, PDAC, CRC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)

The initial trial specifically mentioned these mutations:

KRAS G12A, KRAS G12D, KRAS G12R, KRAS G12S, and KRAS G12V

Spots confirmed as well in KRAS G13D as well as NRAS

NOTE: All interventional clinical trials involve risk so please consult with your medical oncologist.

NCT05379985 TRIAL LISTING

https://clinicaltrials.gov/ct2/show/NCT05379985

Press Release and Slide Presentation from Revolution Medicine, April 2022 #AACR22 meeting.

https://www.revmed.com/media/direct-targeting-kras-g12x-mutant-cancers-rmc-6236-first-class-ras-selective-orally

Revolution Medicines: RMC-6236 Pancreatic Cancer Update to Support Pivotal Phase 3 Trial

Slides:

The slides present info on those patients that are KRAS G12X (e.g. G12V, G12R). They also report out "RAS Mutant" defined as patients with G12X, G13X or Q61X PDAC

https://ir.revmed.com/static-files/eeeb0690-0ef4-44b8-b5fe-8d11d8df3c9a?fbclid=IwY2xjawFn7cxleHRuA2FlbQIxMAABHTWqBgoJFje56iP2y_wF8k9cpa04hsOiSMiwanY2ZwYHub6Si2ltI3a2VQ_aem_t_I-_B6ryZX9lN8TQyH0RQ

ESMO October 2023

REVOLUTION MEDICINE scientific presentation

Preliminary Safety and Pharmacokinetic Profiles of RMC-6236, a First-in-class, RAS-selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Solid Tumors on the Phase 1 Trial RMC-6236-001

poster:

https://s3.us-west-2.amazonaws.com/.../ENA_2023_RMC-6236.pdf

PRELIMINARY RESULTS FOR PHASE 1 TRIAL . (Feb 2023)

8/12 patients were KRAS G12D patients - NSLC and pancreatic

https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-fourth-quarter-and-full-year-2022?fbclid=IwAR2xFzGkjBO3Cp2PQD5GG5aTyC8LsUh5ncNSi7gRHD_DQxJlI1_X6A-8ajk

Corporate Presenation 2/27/23

First 23 minutes explains that response in other KRAS G12C targeted therapies have been more robust in NSLC and pancreatic cancer.

The webinar also discussed the one patient with an unusual serious side effect

https://ir.revmed.com/events-and-presentations

SLIDE DECK Feb 2023

REVOLUTION MEDICINES, INC. 2022 Q4 - RESULTS - EARNINGS CALL PRESENTATION

https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2023/ENA_2023_RMC-6236.pdf?fbclid=IwY2xjawFn8GtleHRuA2FlbQIxMAABHSzx38S_Y3M0zumGvuIpVTSLcvBptautwQhZlo8117Z0_SxyFybq958k3Q_aem_54DQeUjKCQv_0BnScbA8jg